120951-86-2

Upstream product

• 57918-73-7 3-acetoxy-cyclohex-2-enone 
• 69739-34-0 t-butyldimethylsiyl triflate 
• 124-40-3 dimethyl amine 
• 109-89-7 diethylamine 
• 103-49-1 dibenzylamine 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 108-46-3 recorcinol 
• 103-67-3 benzyl-methyl-amine 

Downstream Products

• 1366234-66-3 ((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-phenylene)bis(oxy))bis(tert-butyldimethylsilane) 
• 1352571-55-1 (+/-)-3-(4-(4-methoxybenzyloxy)-5-methylpyrimidin-2-yl)-5-(tetrahydrofuran-3-yloxy)phenol 
• 1352571-39-1 2-(3,5-bis(tert-butyldimethylsilyloxy)phenyl)-4-(4-methoxybenzyloxy)-5-methylpyrimidine 
• 1352571-40-4 5-(4-(4-methoxybenzyloxy)-5-methylpyrimidin-2-yl)benzene-1,3-diol 
• 1352571-41-5 3-(4-(4-methoxybenzyloxy)-5-methylpyrimidin-2-yl)-5-(4-(methylsulfonyl)phenoxy)phenol 
• 1352570-45-6 5-methyl-2-{3-[4-(methylsulfonyl)phenoxy]-5-(tetrahydrofuran-3-yloxy)phenyl}pyrimidin-4(3H)-one 
• 1352570-48-9 5-methyl-2-(3-(4-(methylsulfonyl)phenoxy)-5-(tetrahydro-2H-pyran-4-yloxy)phenyl)pyrimidin-4(3H)-one 
• 1352571-66-4 4-(4-methoxybenzyloxy)-5-methyl-2-(3-(4-(methylsulfonyl)phenoxy)-5-(tetrahydro-2H-pyran-4-yloxy)phenyl)pyrimidine 
• 1147862-00-7 1,5-bis((tert-butyldimethylsilyl)oxy)cyclohexa-1,4-diene 
• 108-46-3 recorcinol 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF

The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and infectious diseases, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.

NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF

The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and infectious diseases, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.

Asymmetric Synthesis and Structure Revision of Guignardone H and I: Development of a Chiral 1,3-Diketone Possessing C2 Symmetry

A novel chiral 1,3-diketone possessing C2 symmetry was synthesized and utilized in the asymmetric synthesis of guignardone H and I by employing sequential condensation-6?-electrocyclization reactions with the novel 1,3-diketone followed by ster

COMPOUNDS AND THERAPEUTIC USES THEREOF

The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and a disease or disorder mediated and/or caused by an infective agent, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.

2-(3,5-DISUBSTITUTEDPHENYL)PYRIMIDIN-4(3H)-ONE DERIVATIVES

O N NH R3 R2 O R1 168 ABSTRACT The present invention provides a 2-(3,5-disubstitutedphenyl)pyrimidin- 4(3H)-one compound of Formula (I) 5 (I) or a pharmaceutically acceptable salt thereof wherein R 1, R2 and R3 are as defined herein. The compounds of Formula (I) have been found to act as glucokinase activators. Consequently, the compounds of Formula (I) and 10 the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucokinase.

Aromatization of enamines promoted by a stoichiometric amount of palladium(II) salts: A novel method for the synthesis of aromatic amines

Enamines (1a-r) prepared from cyclohexanones, cyclohexane-1,3-diones, or tetralones led to arylamines (2a-r) in one pot when treated with a stoichiometric amount of palladium salts [PdCl2-(MeCN)2] in acetonitrile in the presence of triethylamine at room temperature or at elevated temperature, in some cases for 5 min to 2 h. The initial electrophilic attack of palladium chloride on the β-carbon of the enamines led to a σ-palladium species (8) which triggered a series of reactions (→ 9 → 19 → 11 → 12) destined for aromatization to give 2a-r in good yields. The intervention of such a σ-palladium species has been attested by a trapping experiment. On the basis of this reaction mechanism, we have developed another new process capable of transforming acyclic compounds having 6-en-2-one frameworks (16, 23, 25) to arylamines (2s-u) when their enamines were treated under the similar conditions as above, featuring again the formation of σ-palladium species such as 8 as the initial key intermediate.